The aim was to assess the safety and immunogenicity of the BNT162b2 (Pfizer–BioNTech) vaccine in patients with cancer.
|
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00213-8/fulltext |
|
April 27, 2021, The Lancet Oncology |
|
Vaccine Safety |
|
prospective cohort study |
|
London, UK |
|
Level IV: cohort study |
|
The aim was to assess the safety and immunogenicity of the BNT162b2 (Pfizer–BioNTech) vaccine in patients with cancer. |
|
They included patients with cancer and healthy controls (mostly health-care workers) from three London hospitals in this prospective longitudinal observational study to allow for comparisons of vaccine immunogenicity and safety. Participants were eligible for the BNT162b2 vaccine, were screened, and were approached to participate in the SOAP-02 study |
| Results |
|
|
The low vaccine efficacy reported for cancer patients receiving seasonal vaccines, and imply that single-dose BNT162b2 vaccination leaves most cancer patients immunologically unprotected. |
|
The objective of this prospective observational study was to evaluate the safety and immunogenicity of the BNT162b2 (Pfizer–BioNTech) vaccine in cancer patients. They included 151 patients with solid and hematological cancers, providing the first insights into the antibody and T-cell responses to the mRNA-based SARS-CoV-2 BNT162b2 vaccine, as well as its safety in an immunocompromised patient population, to our knowledge. Furthermore, they assess the impact of different dosing schedules in this population. One 30 g dose of the BNT162b2 vaccine yields poor efficacy in cancer patients, as measured by seroconversion rates, viral neutralisation capacity, and T-cell responses at 3 and 5 weeks after the first inoculum. Immunogenicity significantly increased in patients with solid cancer within 2 weeks of a vaccine boost on day 21 after the first dose. |